Incidence of primary sclerosing cholangitis: a systematic review and meta-analysis
- PMID: 21351115
- DOI: 10.1002/hep.24247
Incidence of primary sclerosing cholangitis: a systematic review and meta-analysis
Abstract
Incidence studies of primary sclerosing cholangitis (PSC) are important for describing the disease's burden and for shedding light on the disease's etiology. The purposes of this study were to conduct a systematic review of the incidence studies of PSC with a meta-analysis and to investigate possible geographic variations and temporal trends in the incidence of the disease. A systematic literature search of MEDLINE (1950-2010) and Embase (1980-2010) was conducted to identify studies investigating the incidence of PSC. The incidence of PSC was summarized with an incidence rate (IR) and 95% confidence intervals. The test of heterogeneity was performed with the Q statistic. Secondary variables extracted from the articles included the following: the method of case ascertainment, the country, the time period, the age, the male/female incidence rate ratio (IRR), and the incidence of PSC subtypes (small-duct or large-duct PSC and inflammatory bowel disease). Stratified and sensitivity analyses were performed to explore heterogeneity between studies and to assess effects of study quality. Time trends were used to explore differences in the incidence across time. The search retrieved 1669 potentially eligible citations; 8 studies met the inclusion criteria. According to a random-effects model, the pooled IR was 0.77 (0.45-1.09) per 100,000 person-years. However, significant heterogeneity was observed between studies (P < 0.001). Sensitivity analyses excluding non-population-based studies increased the overall IR to 1.00 (0.82-1.17) and eliminated the heterogeneity between studies (P = 0.08). The IRR for males versus females was 1.70 (1.34-2.07), and the median age was 41 years (35-47 years). All studies investigating time trends reported an overall increase in the incidence of PSC.
Conclusion: The incidence of PSC is similar in North American and European countries and continues to increase over time. Incidence data from developing countries are lacking, and this limits our understanding of the global incidence of PSC.
Copyright © 2011 American Association for the Study of Liver Diseases.
Similar articles
-
Global incidence, prevalence and features of primary sclerosing cholangitis: A systematic review and meta-analysis.Liver Int. 2021 Oct;41(10):2418-2426. doi: 10.1111/liv.15007. Epub 2021 Jul 19. Liver Int. 2021. PMID: 34224208
-
Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review.J Hepatol. 2012 May;56(5):1181-1188. doi: 10.1016/j.jhep.2011.10.025. Epub 2012 Jan 13. J Hepatol. 2012. PMID: 22245904 Review.
-
The burden of large and small duct primary sclerosing cholangitis in adults and children: a population-based analysis.Am J Gastroenterol. 2007 May;102(5):1042-9. doi: 10.1111/j.1572-0241.2007.01103.x. Epub 2007 Feb 21. Am J Gastroenterol. 2007. PMID: 17313496
-
Incidence and prevalence of primary sclerosing cholangitis in a defined adult population in Sweden.Hepatology. 2010 Aug;52(2):571-7. doi: 10.1002/hep.23678. Hepatology. 2010. PMID: 20683956
-
Geoepidemiology of primary sclerosing cholangitis: a critical review.J Autoimmun. 2013 Oct;46:35-40. doi: 10.1016/j.jaut.2013.07.005. Epub 2013 Aug 7. J Autoimmun. 2013. PMID: 23932346 Review.
Cited by
-
Suppression of systemic inflammation and signs of acute and chronic cholangitis by multi-kinase inhibitor 1-(4-Cl-benzyl)-3-chloro-4-(CF3-phenylamino)-1H-pyrrole-2,5-dione.Mol Cell Biochem. 2021 Aug;476(8):3021-3035. doi: 10.1007/s11010-021-04144-y. Epub 2021 Apr 1. Mol Cell Biochem. 2021. PMID: 33792809
-
Rare but heard: using asynchronous virtual focus groups, interviews and roundtable discussions to create a personalised psychological intervention for primary sclerosing cholangitis: a protocol.BMJ Open. 2019 Oct 2;9(10):e031417. doi: 10.1136/bmjopen-2019-031417. BMJ Open. 2019. PMID: 31578198 Free PMC article.
-
Protein and miRNA profile of circulating extracellular vesicles in patients with primary sclerosing cholangitis.Sci Rep. 2022 Feb 22;12(1):3027. doi: 10.1038/s41598-022-06809-0. Sci Rep. 2022. PMID: 35194091 Free PMC article.
-
Cholangiocarcinoma in Patients with Primary Sclerosing Cholangitis (PSC): a Comprehensive Review.Clin Rev Allergy Immunol. 2020 Feb;58(1):134-149. doi: 10.1007/s12016-019-08764-7. Clin Rev Allergy Immunol. 2020. PMID: 31463807 Review.
-
Treatment of primary sclerosing cholangitis combined with inflammatory bowel disease.Intest Res. 2023 Oct;21(4):420-432. doi: 10.5217/ir.2023.00039. Epub 2023 Sep 1. Intest Res. 2023. PMID: 37519211 Free PMC article. Review.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous